Literature DB >> 11006018

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.

D Flieger1, S Renoth, I Beier, T Sauerbruch, I Schmidt-Wolf.   

Abstract

With a new flow cytometric cytotoxicity assay, we examined the mechanism of action of chimeric mouse human anti-CD20 monoclonal antibody IDEC-C2B8. IDEC-C2B8 alone induced direct cytotoxicity in four of eight examined CD20-expressing lymphoma cell lines (RAJI, DAUDI, JOK-1, and WT100) at a concentration above 100 ng/ml. Moreover, after 4 h incubation in human serum, only a moderate complement-dependent cellular cytotoxicity (CDCC) was observed, whereas cytotoxicity increased markedly after 3 days of culture, indicating that combined direct cytotoxicity and CDCC were responsible. IDEC-C2B8 induced an effective antibody-dependent cellular cytotoxicity (ADCC) in seven of eight tested lymphoma cell lines when peripheral blood mononuclear cells were used as effector cells. ADCC was moderately enhanced by cytokine interleukin-2, whereas interleukin-12, interferon-alpha, and GM-CSF had no influence. Interestingly, we could demonstrate a correlation between CD32 expression on lymphoma cell lines and IDEC-C2B8-induced direct cytotoxicity, indicating that crosslinking of CD20 with CD32 may be involved in the mechanism of cytotoxicity. We propose that direct cytotoxicity, CDCC, and ADCC result in the marked elimination of CD20-expressing tumor cells observed after treatment with IDEC-C2B8. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006018     DOI: 10.1006/cimm.2000.1693

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  28 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 2.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 3.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors:  Hyunbo Shim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

Review 4.  Rituximab: mechanism of action.

Authors:  George J Weiner
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

Review 5.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Authors:  Ezogelin Oflazoglu; Laurent P Audoly
Journal:  MAbs       Date:  2010-01-30       Impact factor: 5.857

Review 6.  Rituximab resistance.

Authors:  Andrew R Rezvani; David G Maloney
Journal:  Best Pract Res Clin Haematol       Date:  2011-04-13       Impact factor: 3.020

Review 7.  Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

8.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

10.  Expanded use of rituximab in the management of non-Hodgkin lymphoma.

Authors:  Dennis A Eichenauer; Andreas Engert; Holger Schulz
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.